{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:36:01Z","timestamp":1781001361044,"version":"3.54.1"},"reference-count":51,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3913,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>\n                    The emergence of extended\u2010spectrum \u03b2\u2010lactamase (ESBL)\u2010producing Enterobacteriaceae, particularly\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    and\n                    <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                    , presents significant diagnostic and therapeutic challenges to the management of infections due to these organisms. Detection of resistant isolates is difficult based on routine susceptibility testing performed by a clinical microbiology laboratory. In addition, the utility of penicillins, cephalosporins, and aztreonam in treating serious infections due to these organisms is uncertain due to reports of treatment failure despite apparent in vitro susceptibility. A critical evaluation of the English literature was performed on treatment outcomes associated with ESBL\u2010producing Enterobacteriaceae. Imipenem and extended\u2010spectrum cephalosporins were commonly administered. Discordant outcomes in relation to in vitro susceptibility of the agent did not occur exclusively with cephalosporins but with all drugs including imipenem. Until more outcome data are available, drug selection must take into consideration whether or not an outbreak is occurring and whether therapy is empirical or definitive.\n                  <\/jats:p>","DOI":"10.1592\/phco.21.6.583.34537","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T06:25:36Z","timestamp":1086762336000},"page":"583-592","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Therapeutic Challenges Associated with Extended\u2010Spectrum, \u03b2\u2010Lactamase\u2010Producing\n                    <i>Escherichia coli<\/i>\n                    and\n                    <i>Klebsiella pneumoniae<\/i>"],"prefix":"10.1002","volume":"21","author":[{"given":"Annie","family":"Wong\u2010Beringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.8.4.557"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01690090"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.12.4065-4070.1999"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/313559"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00044-2"},{"key":"e_1_2_1_7_2","unstructured":"JacobyG.A. BushK.Amino acid sequences for TEM SHV and OXA extended\u2010spectrum and inhibitor resistant \u03b2\u2010lactamases. Available fromhttp:www.lahey.orgstudieswebt.htm. AccessedMarch 2001."},{"key":"e_1_2_1_8_2","first-page":"215","volume-title":"Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy, San Francisco, September 26\u201329, 1999","author":"Steward C.D.","year":"1999"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.12.120S.31699"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-5-199309010-00015"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(97)00234-4"},{"key":"e_1_2_1_12_2","volume-title":"Approved standard M\u2010100\u2010S10: performance standards for antimicrobial susceptibility testing","author":"National Committee for Clinical Laboratory Standards.","year":"2000"},{"key":"e_1_2_1_13_2","first-page":"1167","article-title":"Laboratory capacity to detect antimicrobial resistance, 1998","volume":"48","author":"Centers for Disease Control and Prevention.","year":"2000","journal-title":"MMWR"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.1.164"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1187"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000007147"},{"key":"e_1_2_1_17_2","volume-title":"In vitro bacteriostatic and bactericidal activity of cefotetan against enterobacteria with extended\u2010spectrum \u03b2\u2010lactamases [abstr]","author":"Privitera G.","year":"1999"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000239575"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.1.241"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1883"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.4.581"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.2.195"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1243"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.11.2663"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01643247"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1290"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/517217"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.1.203"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.9.1451"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/20.6.919"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/514754"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.9.1991"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)90891-9"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/jcm.34.3.564-568.1996","article-title":"Molecular epidemiology of Klebsiella pneumoniae producing SHV\u20105 \u03b2\u2010lactamase: parallel outbreaks due to multiple plasmid transfer","volume":"34","author":"Prodinger W.M.","year":"1996","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/jcm.34.2.358-363.1996","article-title":"Hospital outbreak of Klebsiella pneumoniae resistant to broad\u2010spectrum cephalsoporins and \u03b2\u2010lactam\u2010\u03b2\u2010lactamase inhibitor combinations by hyperproduction of SHV\u20105 \u03b2\u2010lactamase","volume":"34","author":"French G.L.","year":"1996","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1128\/jcm.31.2.179-184.1993","article-title":"Molecular epidemiology of plasmid spread among extended broad\u2010spectrum \u03b2\u2010lactamase\u2010producing Klebsiella pneumoniae isolates in a pediatric hospital","volume":"31","author":"Bingen E.H.","year":"1993","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1128\/AAC.42.1.53","article-title":"Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended\u2010spectrum \u03b2\u2010lactamases","volume":"42","author":"Pena C.","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2193"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/fn.80.1.F64"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-5-199309010-00001"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.35.8.2061-2067.1997"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/JCM.37.12.4020-4027.1999","article-title":"Bacteremia due to extended\u2010spectrum \u03b2\u2010lactamase\u2010producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV\u20105 and TEM\u20101 genes","author":"Siu L.K.","year":"1999","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_43_2","volume-title":"Activity of antibiotic combinations against extended\u2010spectrum \u03b2\u2010lactamase (ESBL)\u2010producing Klebsiella pneumonia [abstr]","author":"Paterson D.L.","year":"1999"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.14.1233"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90694-7"},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1128\/AAC.40.2.342","article-title":"In vivo selection of porin\u2010deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded\u2010spectrum cephalosporins","volume":"40","author":"Martinez\u2010Martinez L.","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_1_47_2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1128\/jcm.35.2.508-510.1997","article-title":"Study of an outbreak of cefoxitin\u2010resistant Klebsiella pneumoniae in a general hospital","volume":"35","author":"Gazouli M.","year":"1997","journal-title":"J Clin Microbiol"},{"key":"e_1_2_1_48_2","first-page":"426","volume-title":"Infections caused by ESBL\u2010and AmpC\u2010producing Enterobacteriaceae treated with cefepime [abstr]","author":"Joshi M.","year":"2000"},{"key":"e_1_2_1_49_2","first-page":"167","volume-title":"Clinical outcome of patients with extended\u2010spectrum \u03b2\u2010lactamase (ESBL)\u2010producing Klebsiella pneumoniae and Escherichia coli bacteremia after treatment with expanded\u2010spectrum cephalosporins [abstr]","author":"Wong\u2010Beringer A.","year":"1999"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1086\/313719"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.563"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)62567-6"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.6.583.34537","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.6.583.34537","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:40Z","timestamp":1761069700000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.6.583.34537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1592\/phco.21.6.583.34537"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.6.583.34537","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}